Logo
x

Search

Subscribe Now

bla

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

  • November 2, 2021
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

  • October 25, 2021
Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related M...

  • October 5, 2021
Coherus Reports the US FDA's Acceptance of BLA for CHS-201 (biosimilar, ranibizumab)

Coherus Reports the US FDA's Acceptance of BLA for CHS-201 (biosimilar, ranibizumab)

  • October 1, 2021
Eisai Initiates Rolling Submission of BLA to the US FDA for Lecanemab to Treat Alzheimer's Disease

Eisai Initiates Rolling Submission of BLA to the US FDA for Lecanemab to Treat Alzheimer's Disease

  • September 28, 2021
BeiGene and Novartis Report the US FDA's Acceptance of BLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma

BeiGene and Novartis Report the US FDA's Acceptance of BLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma

  • September 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.